関連する実験動画

Updated: Feb 24, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

潰瘍性大腸炎に対するアルゴリプチンの再利用:マイクロRNA,抗炎症,および障壁回復機構の関与

Meshal Awadh Ghayeb Alenezi¹, Mohamed Gamal El-Din Ewees², Elsayed K El-Sayed³

¹Naif Al Nader Medical Pharmacies Group, Riyadh, Kingdom of Saudi Arabia.

Naunyn-Schmiedeberg's archives of pharmacology

|February 22, 2026

まとめ

DPP-4阻害剤であるアルゴリプチンは,潰瘍性大腸炎 (UC) 治療において有望であることが示されています. 炎症と酸化ストレスを軽減し,マイクロRNAを調節し,腸の障壁機能を回復することにより,粘膜の治癒を促進します.

科学分野:

胃腸内科胃腸内科
免疫学免疫学とは
薬理学薬理学とは

背景:

潰瘍性大腸炎 (UC) は,慢性的な炎症,酸化ストレス,および障壁障害を含み,現在の治療法は粘膜の治癒を達成する上で制限に直面しています.
UCにおける免疫応答と酸化経路の両方を調節できる新しい治療薬が必要である.
ディペプチジルペプチダゼ-4 (DPP-4) 阻害剤は,アルゴリプチンと同様に,主に糖尿病に使用されますが,抗炎症的特性を有することがあります.

研究の目的:

酸誘発性潰瘍性大腸炎のラットモデルにおけるアルゴリプチンの予防効果を評価する.
アルゴリプチンのマイクロRNAの調節,サイトカインのバランス,およびUCにおける上皮壁の整合性への影響を調査する.
アルゴリプチンの抗炎症および抗酸化メカニズムを調べることで,UCの治療薬としてのアルゴリプチンの可能性を調査する.

主な方法:

48匹のWistarラットは,対照群,アルグリプチンのみ,UC,UC+スルファサラジン,および2つのUC+アルグリプチン用量群に分けられました.
潰瘍性大腸炎は,酸を用いて誘発され,その後アルゴリプチンまたはスルファサラジンが投与されました.
結腸損傷,炎症誘発性サイトカイン (TNF-α,IL-6,IL-17),粘着分子 (VCAM-1,ICAM-1),酸化ストレスマーカー (MDA,SOD,CAT),IL-10レベル,緊密な結合タンパク質 (ZO-1,オークルジン),および特定のマイクロRNA (miR-145,miR-200a,miR-34a) を評価した.

主要な成果:

アルゴリプチン治療はUC誘発の結腸内組織病理学的損傷と潰瘍指数を有意に軽減しました.
アルゴリプチンは,マロンディアルデヒドを減少させ,抗酸化酵素 (SOD, CAT) を強化することによって,リドックスホメオスタシスを回復させた.
アルゴリプチンは,TNF-α/IL-17を抑制し,IL-10を増加させ,ADAM-17をダウンレギュレーションし,HO-1をアップレギュレーションすることにより,免疫信号のバランスを取り戻しました. また,特定のマイクロRNA (miR-145,miR-200a,miR-34a) を調節し,緊密な結合タンパク質の発現を改善し,バリア機能を保持しました.

結論:

アルゴリプチンは,潰瘍性大腸炎のラットモデルで重要な予防および治療効果を示しています.
アログリプチンの抗炎症,抗酸化,粘膜保護機構は,マイクロRNA発現を調節する能力と関連しています.
アルゴリプチンは,潰瘍性大腸炎患者に対する潜在的な治療的利点を持つDPP-4阻害剤として再利用するための約束を示しています.

キーワード:

アルゴリプチン (Alogliptin) とは DPP-4 阻害剤は,DPP-4 阻害剤として使用されています.オキシダティブ・ストレスは,潰瘍性大腸炎 (Ulcerative colitis) とは潰瘍性大腸炎 (Ulcerative colitis) とは潰瘍性大腸炎 (Ulcerative colitis) とは大腸炎 (Ulcerative colitis) とは

さらに関連する動画

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids

Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids

Published on: June 2, 2023

関連する概念動画

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...